This Article Full Text Full Text (PDF) All Versions of this Article: 110/20/3252    most recent 01.CIR.0000147232.75456.B3v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Van Lenten, B. J. Articles by Fogelman, A. M. Search for Related Content PubMed PubMed Citation Articles by Van Lenten, B. J. Articles by Fogelman, A. M. Pubmed/NCBI databases Substance via MeSH Related Collections Apoptosis Pathophysiology Risk Factors Cell signalling/signal transduction Lipid and lipoprotein metabolism Other Vascular biology

(Circulation. 2004;110:3252-3258.)
© 2004 American Heart Association, Inc.

Molecular Cardiology

D-4F, an Apolipoprotein A-I Mimetic Peptide, Inhibits the Inflammatory Response Induced by Influenza A Infection of Human Type II Pneumocytes

Brian J. Van Lenten, PhD; Alan C. Wagner; Mohamad Navab, PhD; G.M. Anantharamaiah, PhD; Eric Ka-Wai Hui, PhD; Debi P. Nayak, PhD; Alan M. Fogelman, MD

From the Departments of Medicine (B.J.V.L., A.C.W., M.N., A.M.F.) and Microbiology, Immunology, and Molecular Genetics (E.K.H., D.P.N.), David Geffen School of Medicine at UCLA, Los Angeles, Calif, and the Departments of Medicine, Biochemistry, and Molecular Genetics and the Atherosclerosis Research Unit (G.M.A.), University of Alabama, Birmingham.

Correspondence to Brian J. Van Lenten, PhD, 47-123 CHS, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095-1679. E-mail bvanlent{at}mednet.ucla.edu

Received December 30, 2003; de novo received February 17, 2004; accepted April 13, 2004.

Background— Evidence suggests that apolipoprotein A-I (apoA-I) and HDL play important roles in modulating inflammation. We previously reported that an apoA-I mimetic peptide, D-4F, reduced inflammatory responses to influenza virus in mice. To further define the antiinflammatory activity of D-4F, a human alveolar type II cell line, A549, was used.

Methods and Results— Cells were either uninfected or infected with influenza A in the presence or absence of D-4F. Cells treated with D-4F were more viable, and virus-induced cytokine production was suppressed by D-4F. Caspases associated with cytokine production were activated after infection but suppressed by D-4F treatment. Infected A549 cells showed dramatic increases in cellular phospholipid secretion into the media. When infected cells were incubated with D-4F, secretion of parent nonoxidized, noninflammatory phospholipids was unaltered, but production of proinflammatory oxidized phospholipids was inhibited.

Conclusions— Type II pneumocytes respond to influenza A infection by activating caspases and secreting cytokines and cellular phospholipids into the extracellular environment, including oxidized phospholipids that evoke inflammatory responses. D-4F treatment inhibited these events. Our results suggest that apoA-I and apoA-I mimetic peptides such as D-4F are antiinflammatory agents that may have therapeutic potential.

Key Words: apolipoproteins • atherosclerosis • infection • lipoproteins • epithelium

This article has been cited by other articles:

				V. K. Mishra, M. N. Palgunachari, N. R. Krishna, J. Glushka, J. P. Segrest, and G. M. Anantharamaiah Effect of Leucine to Phenylalanine Substitution on the Nonpolar Face of a Class A Amphipathic Helical Peptide on Its Interaction with Lipid: HIGH RESOLUTION SOLUTION NMR STUDIES OF 4F-DIMYRISTOYLPHOSPHATIDYLCHOLINE DISCOIDAL COMPLEX J. Biol. Chem., December 5, 2008; 283(49): 34393 - 34402. [Abstract] [Full Text] [PDF]

				B. J. Van Lenten, A. C. Wagner, C.-L. Jung, P. Ruchala, A. J. Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamaiah, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I J. Lipid Res., November 1, 2008; 49(11): 2302 - 2311. [Abstract] [Full Text] [PDF]

				G. M. Buga, J. S. Frank, G. A. Mottino, A. Hakhamian, A. Narasimha, A. D. Watson, B. Yekta, M. Navab, S. T. Reddy, G. M. Anantharamaiah, et al. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet J. Lipid Res., January 1, 2008; 49(1): 192 - 205. [Abstract] [Full Text] [PDF]

				D. Weihrauch, H. Xu, Y. Shi, J. Wang, J. Brien, D. W. Jones, S. Kaul, R. A. Komorowski, M. E. Csuka, K. T. Oldham, et al. Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1432 - H1441. [Abstract] [Full Text] [PDF]

				G. M. Buga, J. S. Frank, G. A. Mottino, M. Hendizadeh, A. Hakhamian, J. H. Tillisch, S. T. Reddy, M. Navab, G. M. Anantharamaiah, L. J. Ignarro, et al. D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet J. Lipid Res., October 1, 2006; 47(10): 2148 - 2160. [Abstract] [Full Text] [PDF]

				M. Navab, G.M. Anantharamaiah, and A. M. Fogelman An Apolipoprotein A-I Mimetic Works Best in the Presence of Apolipoprotein A-I Circ. Res., November 25, 2005; 97(11): 1085 - 1086. [Full Text] [PDF]

				B. J. Ansell, K. E. Watson, A. M. Fogelman, M. Navab, and G. C. Fonarow High-Density Lipoprotein Function: Recent Advances J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1792 - 1798. [Abstract] [Full Text] [PDF]

				M. Navab, G.M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, A. C. Wagner, S. Hama, G. Hough, E. Bachini, D. W. Garber, V. K. Mishra, et al. An Oral ApoJ Peptide Renders HDL Antiinflammatory in Mice and Monkeys and Dramatically Reduces Atherosclerosis in Apolipoprotein E-Null Mice Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1932 - 1937. [Abstract] [Full Text] [PDF]